| Predictors of pharmacoresistant epilepsy N Hitiris, R Mohanraj, J Norrie, GJ Sills, MJ Brodie Epilepsy research 75 (2-3), 192-196, 2007 | 629 | 2007 |
| Diagnosing refractory epilepsy: response to sequential treatment schedules R Mohanraj, MJ Brodie European journal of neurology 13 (3), 277-282, 2006 | 398 | 2006 |
| Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study R Mohanraj, J Norrie, LJ Stephen, K Kelly, N Hitiris, MJ Brodie The Lancet Neurology 5 (6), 481-487, 2006 | 280 | 2006 |
| Mortality in epilepsy N Hitiris, R Mohanraj, J Norrie, MJ Brodie Epilepsy & behavior 10 (3), 363-376, 2007 | 243 | 2007 |
| Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug Treatment GJ Sills, R Mohanraj, E Butler, S McCrindle, L Collier, EA Wilson, ... Epilepsia 46 (5), 643-647, 2005 | 234 | 2005 |
| Anaesthesia and epilepsy A Perks, S Cheema, R Mohanraj British journal of anaesthesia 108 (4), 562-571, 2012 | 165 | 2012 |
| The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non … A Marson, G Burnside, R Appleton, D Smith, JP Leach, G Sills, ... The Lancet 397 (10282), 1375-1386, 2021 | 159 | 2021 |
| The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority … A Marson, G Burnside, R Appleton, D Smith, JP Leach, G Sills, ... The Lancet 397 (10282), 1363-1374, 2021 | 158 | 2021 |
| Early predictors of outcome in newly diagnosed epilepsy R Mohanraj, MJ Brodie Seizure 22 (5), 333-344, 2013 | 129 | 2013 |
| Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention JP Leach, R Mohanraj, W Borland Epilepsia 53, 48-57, 2012 | 125 | 2012 |
| Pharmacological outcomes in newly diagnosed epilepsy R Mohanraj, MJ Brodie Epilepsy & Behavior 6 (3), 382-387, 2005 | 118 | 2005 |
| Measuring the efficacy of antiepileptic drugs R Mohanraj, MJ Brodie Seizure 12 (7), 413-443, 2003 | 106 | 2003 |
| Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy CRE Gall, O Jumma, R Mohanraj Seizure 22 (3), 217-220, 2013 | 102 | 2013 |
| Pharmacological outcomes in older people with newly diagnosed epilepsy LJ Stephen, K Kelly, R Mohanraj, MJ Brodie Epilepsy & behavior 8 (2), 434-437, 2006 | 87 | 2006 |
| Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies M Carreño, CG Bien, AA Asadi-Pooya, M Sperling, P Marusic, M Elisak, ... Epilepsy research 129, 101-105, 2017 | 83 | 2017 |
| Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non‐pediatric setting R Mohanraj, MJ Brodie Acta neurologica scandinavica 115 (3), 204-208, 2007 | 83 | 2007 |
| Outcomes in newly diagnosed localization-related epilepsies R Mohanraj, MJ Brodie Seizure 14 (5), 318-323, 2005 | 78 | 2005 |
| Clinical experience with perampanel: focus on psychiatric adverse effects H Coyle, P Clough, P Cooper, R Mohanraj Epilepsy & Behavior 41, 193-196, 2014 | 71 | 2014 |
| Levetiracetam in refractory epilepsy: a prospective observational study R Mohanraj, PG Parker, LJ Stephen, MJ Brodie Seizure 14 (1), 23-27, 2005 | 63 | 2005 |
| Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications JB Lilleker, V Biswas, R Mohanraj Seizure 23 (8), 598-602, 2014 | 60 | 2014 |
